Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
SYRE submitted a Form 144 notice concerning the proposed sale of 45,000 shares of Common Stock. The filing shows these shares trace to previously exercised stock options dated 06/15/2023.
The excerpt also records two Rule 10b5-1 transactions by Cameron W. Turtle: 15,000 shares sold on 05/01/2026 for $1,070,506.50 and 15,000 shares sold on 06/01/2026 for $1,056,508.50. Shares outstanding are listed as 86,841,253 as of 07/01/2026.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported an exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options to acquire 15,000 shares of common stock at an exercise price of $14.50 per share, then sold 15,000 shares in open-market transactions.
The sales comprised 10,000 shares at a weighted average price of $87.14 and 5,000 shares at $87.12, with actual trade prices ranging from $86.78 to $87.43. After these trades, he directly held 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
Burrows also continues to hold a stock option originally covering 404,857 shares, with 359,857 option shares remaining after this 15,000‑share exercise. The option had been adjusted for a 1‑for‑25 reverse stock split and vests over several years based on continued employment.
Spyre Therapeutics filed a Form S-3ASR registering up to $500,000,000 of common stock for sale under an at-the-market Sales Agreement with TD Cowen. The registration also carries forward $36,550,000 of unsold securities from a prior registration under Rule 415(a)(6).
The prospectus shows the Nasdaq last sale price of the common stock at $88.67 per share on June 25, 2026, and states shares outstanding of 87,936,477 as of June 24, 2026. The prospectus supplement describes sales of common stock from time to time through TD Cowen as agent under an at-the-market program.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice for the sale of 15,000 shares of Common stock in connection with a stock option exercise to occur on 06/25/2026. The filing lists three prior sales by Scott Burrows totaling 27,500 shares on 04/01/2026, 05/01/2026, and 06/01/2026 with aggregate proceeds reported.
SYRE filing a notice of proposed sale of Common shares under Rule 144. The excerpt lists historical and planned dispositions tied to corporate events: 378,421 shares from a reverse merger (06/22/2023), 3,639,680 shares issued in exchange of Series A non-voting convertible preferred stock (04/25/2024), and 666,680 shares from conversion of Series B non-voting convertible preferred stock (06/23/2026). The cover lines show trade/agent details including 4,684,781 (numeric field) and an aggregate dollar figure $399,658,667.00 appearing in the excerpt.
Spyre Therapeutics, Inc. reported Form 4 activity for entities associated with Fairmount Funds Management LLC. Fairmount Healthcare Fund II L.P. converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, based on a 40-to-1 conversion ratio subject to a 9.99% beneficial ownership limitation.
On the same date, Fairmount Healthcare Fund II L.P. sold 4,684,781 shares of Common Stock at $85.31 per share, leaving it with no directly held Common Stock after the transaction, while retaining indirect exposure through Series A Preferred Stock that is convertible into 13,841,800 shares of Common Stock. Fairmount, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Spyre Therapeutics’ major shareholder Fairmount Funds and related individuals updated their ownership disclosures in this Schedule 13D amendment. Fairmount’s Fund II converted 16,667 shares of Series B Preferred Stock into 666,680 common shares for no cash consideration under the preferred stock terms.
On June 23, 2026, Fund II sold 4,684,781 common shares in a block trade at $85.31 per share. After these changes and applying a 9.99% beneficial ownership cap, the reporting group’s position includes 8,581,440 shares issuable from Series A Preferred Stock plus 228,646 option shares, representing up to about 10% of Spyre’s common stock.
The filing also notes that director Peter Harwin resigned from Spyre’s board on May 27, 2026, and states his resignation was not due to any disagreement with the company on its operations, policies, or practices.
Spyre Therapeutics director Michael Thomas Henderson reported an open-market sale of Common Stock. He sold 20,000 shares on June 22, 2026 at a price of $100.00 per share. After this transaction, he directly holds 68,606 shares of Spyre Therapeutics common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating the trades were scheduled in advance rather than timed discretionarily.
SYRE submitted a Form 144 notice relating to proposed resale transactions. The filing lists 20,000 Restricted Stock Units dated 08/28/2024 as securities to be sold and reports prior 10b5-1 sales by Michael Henderson of 80,000 shares on 05/08/2026 for $5,952,034. The filing names Morgan Stanley Smith Barney LLC as the broker and references 06/22/2026 in the header.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY002 in moderately-to-severely active ulcerative colitis. SPY002 met its primary endpoint with a statistically significant 10.7-point reduction in Robarts Histopathology Index score at Week 12 (p<0.0001).
Key secondary measures included clinical remission by modified Mayo Score in 33% of patients and endoscopic improvement in 42%. SPY002 was described as well tolerated: 41.7% of the 48 treated patients experienced treatment-emergent adverse events, with two serious events deemed not drug-related, three drug-related adverse events, no adverse events of special interest, and no deaths.